| Name | Title | Contact Details |
|---|
Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.
Transcept Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
BioDuro, now a PPD company, is a leading integrated drug discovery outsourcing company that provides high-quality, integrated research and development services to meet the growing needs of the global biotechnology and pharmaceutical industries. Together, PPD and BioDuro have the expertise to perform a broad range of research and development services for pharmaceutical and biotech clients from discovery through Phase IV. Founded in 2005, BioDuro has more than 675 employees, the majority of whom are based in Beijing, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro provides high-quality medicinal chemistry, discovery biology, pharmacology, synthesis, bioanalytical and drug safety evaluation services. Its discovery biology services range from reagent generation to assay development to screening and biochemistry.
Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.